We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany
Read MoreHide Full Article
DexCom, Inc. (DXCM - Free Report) , announced that its DexCom G6 continuous glucose monitoring (CGM) system can now connect with the Omnipod 5 Automated Insulin Delivery (AID) system in Germany. The Omnipod 5 AID system, developed by Insulet Corporation (PODD), is the first tubeless AID system that integrates with the DexCom G6 CGM system in Germany to automatically adjust insulin delivery and manage glucose levels both day and night.
The DexCom G6 CGM system is approved for people with type 1 and type 2 diabetes, aged 2 years and older.
The Insulet Corporation’s Omnipod 5 AID system is cleared for individuals with type 1 diabetes, aged 2 years and older. Insulet Corporation achieved clearance for Omnipod 5 AID system based on clinical studies where the system achieved clinically meaningful health outcomes only when it is connected to DexCom CGM.
DexCom added Omnipod AID to its CGM ecosystem in the U.K. in June.
Price Performance
Shares of DexCom have lost 10% year to date against the industry’s 0.3% growth. The S&P 500 Index has gained 18.6% in the same time frame.
Image Source: Zacks Investment Research
DexCom Advantage
The compatibility of the DexCom G6 CGM system and the PODD’s Omnipod 5 AID system offer a new option in Germany for people with diabetes who want to simplify their diabetes management and improve their health outcomes. The combination of these two devices can help users achieve better glucose control, lower A1C, reduce hypoglycemia and hyperglycemia, and increase time in range. Users can also benefit from the convenience, discretion, and flexibility of these tubeless and wireless devices.
With the Omnipod 5 AID system, DexCom strengthens its position as the world’s most connected CGM, providing patients in Germany with more choice and flexibility for observing glucose data and delivering insulin. The benefits are likely to drive demand higher for DexCom G6 CGM system going forward, boosting the company’s top line.
Notable Developments
In July, DexCom announced that its next-generation DexCom G7 CGM system received Health Canada’s approval for people with all types of diabetes, aged two years and above. The DexCom G7 has been built on the performance of DexCom CGM, which has been clinically proven to lower A1C, reduce hypoglycemia (low blood sugar) and improve time in range.
Although approved by Health Canada, DexCom G7 is not yet available for purchase. DexCom Canada is working to make DexCom G7 available to diabetic Canadians by the end of 2023.
The same month, DexCom announced better-than-expected second-quarter results. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Moreover, expansion of coverage for CGM systems during the quarter supported growth that is likely to continue for the rest of 2023. The availability of new sensors like G6 and G7 in new international markets is also boosting revenue growth.
Additionally, the glucose monitoring market presents significant commercial opportunities for DXCM. The company’s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space.
Some better-ranked stocks in the broader medical space are Align Technology (ALGN - Free Report) , HealthEquity, Inc. (HQY - Free Report) and McKesson Corporation (MCK - Free Report) .
ALGN’s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company’s shares have risen 77.8% year to date compared with the industry’s 14.1% growth.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.1%.
The company’s shares have rallied 7.8% year to date against the industry’s 9.4% decline.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%.
The stock has rallied 9.9% year to date compared with the industry’s 14.1% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DexCom's (DXCM) G6 CGM Connects With Omnipod 5 AID in Germany
DexCom, Inc. (DXCM - Free Report) , announced that its DexCom G6 continuous glucose monitoring (CGM) system can now connect with the Omnipod 5 Automated Insulin Delivery (AID) system in Germany. The Omnipod 5 AID system, developed by Insulet Corporation (PODD), is the first tubeless AID system that integrates with the DexCom G6 CGM system in Germany to automatically adjust insulin delivery and manage glucose levels both day and night.
The DexCom G6 CGM system is approved for people with type 1 and type 2 diabetes, aged 2 years and older.
The Insulet Corporation’s Omnipod 5 AID system is cleared for individuals with type 1 diabetes, aged 2 years and older. Insulet Corporation achieved clearance for Omnipod 5 AID system based on clinical studies where the system achieved clinically meaningful health outcomes only when it is connected to DexCom CGM.
DexCom added Omnipod AID to its CGM ecosystem in the U.K. in June.
Price Performance
Shares of DexCom have lost 10% year to date against the industry’s 0.3% growth. The S&P 500 Index has gained 18.6% in the same time frame.
Image Source: Zacks Investment Research
DexCom Advantage
The compatibility of the DexCom G6 CGM system and the PODD’s Omnipod 5 AID system offer a new option in Germany for people with diabetes who want to simplify their diabetes management and improve their health outcomes. The combination of these two devices can help users achieve better glucose control, lower A1C, reduce hypoglycemia and hyperglycemia, and increase time in range. Users can also benefit from the convenience, discretion, and flexibility of these tubeless and wireless devices.
With the Omnipod 5 AID system, DexCom strengthens its position as the world’s most connected CGM, providing patients in Germany with more choice and flexibility for observing glucose data and delivering insulin. The benefits are likely to drive demand higher for DexCom G6 CGM system going forward, boosting the company’s top line.
Notable Developments
In July, DexCom announced that its next-generation DexCom G7 CGM system received Health Canada’s approval for people with all types of diabetes, aged two years and above. The DexCom G7 has been built on the performance of DexCom CGM, which has been clinically proven to lower A1C, reduce hypoglycemia (low blood sugar) and improve time in range.
Although approved by Health Canada, DexCom G7 is not yet available for purchase. DexCom Canada is working to make DexCom G7 available to diabetic Canadians by the end of 2023.
The same month, DexCom announced better-than-expected second-quarter results. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Moreover, expansion of coverage for CGM systems during the quarter supported growth that is likely to continue for the rest of 2023. The availability of new sensors like G6 and G7 in new international markets is also boosting revenue growth.
Additionally, the glucose monitoring market presents significant commercial opportunities for DXCM. The company’s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space.
DexCom, Inc. Price
DexCom, Inc. price | DexCom, Inc. Quote
Zacks Rank & Stocks to Consider
DexCom currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Align Technology (ALGN - Free Report) , HealthEquity, Inc. (HQY - Free Report) and McKesson Corporation (MCK - Free Report) .
Align Technology, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ALGN’s earnings surpassed estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 1.76%. The company’s shares have risen 77.8% year to date compared with the industry’s 14.1% growth.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 9.1%.
The company’s shares have rallied 7.8% year to date against the industry’s 9.4% decline.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 8.1%.
The stock has rallied 9.9% year to date compared with the industry’s 14.1% growth.